Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Rana, Anjum"'
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e10487109bc325ff9193ce17784f275
https://doi.org/10.1158/1078-0432.c.6523520
https://doi.org/10.1158/1078-0432.c.6523520
Autor:
Rhys D.O. Jones, Erica Banks, Crystal Brown, Jason G. Kettle, Wenlin Shao, Sylvie M. Guichard, Evan Barry, Deepa Bhavsar, Aaron Smith, Michael Grondine, Rana Anjum, Venkatesh Pilla Reddy
Summary of plasma protein binding (% unbound) of AZD3229
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a17f5c23820bdafb4fc0f47589397f9
https://doi.org/10.1158/1078-0432.22474907
https://doi.org/10.1158/1078-0432.22474907
Autor:
Rhys D.O. Jones, Erica Banks, Crystal Brown, Jason G. Kettle, Wenlin Shao, Sylvie M. Guichard, Evan Barry, Deepa Bhavsar, Aaron Smith, Michael Grondine, Rana Anjum, Venkatesh Pilla Reddy
Legends for supplementary figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60f675ea4b6f763da330302a1e252133
https://doi.org/10.1158/1078-0432.22474925.v1
https://doi.org/10.1158/1078-0432.22474925.v1
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Supplementary methods, patient information and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624afd3155e4285f1da35f43756a4569
https://doi.org/10.1158/1078-0432.22457162
https://doi.org/10.1158/1078-0432.22457162
Autor:
Rhys D.O. Jones, Erica Banks, Crystal Brown, Jason G. Kettle, Wenlin Shao, Sylvie M. Guichard, Evan Barry, Deepa Bhavsar, Aaron Smith, Michael Grondine, Rana Anjum, Venkatesh Pilla Reddy
Fraction Absorbed (Fabs) as a Function of AZD3229 Dose using GI-SIM tool
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b46a83d9d464bd1765182f72587ecb6
https://doi.org/10.1158/1078-0432.22474910
https://doi.org/10.1158/1078-0432.22474910
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5126f7a2057f9c47635f6496d280ebf0
https://doi.org/10.1158/1078-0432.c.6525524.v1
https://doi.org/10.1158/1078-0432.c.6525524.v1
Autor:
Rhys D.O. Jones, Erica Banks, Crystal Brown, Jason G. Kettle, Wenlin Shao, Sylvie M. Guichard, Evan Barry, Deepa Bhavsar, Aaron Smith, Michael Grondine, Rana Anjum, Venkatesh Pilla Reddy
Purpose:The emergence of secondary mutations is a cause of resistance to current KIT inhibitors used in the treatment of patients with gastrointestinal stromal tumors (GIST). AZD3229 is a selective inhibitor of wild-type KIT and a wide spectrum of pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782aef0a62cbdc796c2c0b0526c0f9a9
https://doi.org/10.1158/1078-0432.c.6528932.v1
https://doi.org/10.1158/1078-0432.c.6528932.v1
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Supplementary Tables. Table S1. In Vitro Kinase IC50 Values (nM) for Native and Mutant Recombinant KIT. Table S2. Summary of Ba/F3 KIT Cell Lines Generated in this Study. Table S3. Summary of IC50 Viability Values in Ba/F3 KIT Cells. Table S4. Summar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595ad2d3921b32e51857d8df11c4a7ca
https://doi.org/10.1158/1078-0432.22457165
https://doi.org/10.1158/1078-0432.22457165
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Supplementary Figures. Figure S1. Chemical structures of imatinib, sunitinib, regorafenib and ponatinib. Figure S2. Expression and activation of KIT in engineered Ba/F3 cells. Figure S3. Ponatinib inhibits the phosphorylation of exon 11primary activa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7299be33d05a34a4969655aa3e5fa0d2
https://doi.org/10.1158/1078-0432.22457168
https://doi.org/10.1158/1078-0432.22457168
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Supplementary Table 1. Brigatinib in vitro activity (IC50s) in a kinase panel (N=289); Supplementary Figure 1. Chemical structures of brigatinib, crizotinib, ceritinib, and alectinib; Supplementary Figure 2. Brigatinib-mediated inhibition of native o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6bdb6961073a5b3e650ddfb94203a6
https://doi.org/10.1158/1078-0432.22463789.v1
https://doi.org/10.1158/1078-0432.22463789.v1